In December, the US Food and Drug Administration (FDA) approved the first two cell-based gene therapies for treating sickle ...

Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

The disease alters the structure of hemoglobin ... but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients.

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

And in December, it shelved a sickle cell treatment similar to Casgevy, the treatment approved in late 2023 from Vertex and CRISPR Therapeutics. Casgevy’s slow rollout — it appears to have ...

bluebird has 3 FDA approved gene therapies: LYFGENIA (lovotibeglogene autotemcel) was FDA approved on the same day as gene-editing therapy CASGEVY ... The weekly market structure low (MSL) buy ...

Slow beginnings for new medicines, especially ones as complex as Casgevy and Lyfgenia, aren’t anything new in the pharmaceutical industry. But the plodding uptake over the therapies’ first ...